# Orforglipron ATTAIN-2: weight loss in type 2 diabetes

Source: https://pepvault.app/research/orforglipron-attain-2-2026

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Orforglipron](https://pepvault.app/research#orforglipron)

Randomized trial · people

# Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In people with type 2 diabetes, this trial found that a once-daily orforglipron pill led to more weight loss than placebo over 72 weeks, with larger losses at higher doses and gut problems as the main side effects that led people to stop.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 1613
- **Published:** 2026
- **Journal:** Lancet

## What they tested

The team tested whether orforglipron, a once-daily GLP-1 receptor agonist pill that is not a peptide, helps adults with type 2 diabetes and excess weight lose weight over 72 weeks.

## How the study was done

A phase 3, double-blind, randomized, placebo-controlled trial run at 136 sites. It enrolled 1613 adults with type 2 diabetes whose BMI was at least 27 kg/m2 and whose HbA1c (a 3-month average of blood sugar) sat between 7% and 10%. Each person took orforglipron 6 mg, 12 mg or 36 mg, or a placebo (a dummy pill), every day for 72 weeks along with lifestyle changes.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

Average body weight changed by -5.1% in the 6 mg arm, -7.0% in the 12 mg arm and -9.6% in the 36 mg arm, compared with -2.5% on placebo (all p<0.0001). These results count every randomized person, including those who stopped treatment. HbA1c and all other planned weight and heart-and-metabolism measures improved significantly with orforglipron. The most common side effects were mild-to-moderate stomach and gut problems, mostly while the dose was being stepped up, and 6.1-9.9% of people on orforglipron stopped because of side effects, compared with 4.1% on placebo.

## What it doesn’t show

The trial only included adults with type 2 diabetes and an HbA1c of 7-10%, so it does not show results in people without diabetes, and all groups also made lifestyle changes. The study was funded by Eli Lilly and Company.

## The paper

Horn et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026.

- [PubMed (PMID 41275875)](https://pubmed.ncbi.nlm.nih.gov/41275875/)
- [The paper (DOI 10.1016/S0140-6736(25)02165-8)](https://doi.org/10.1016/S0140-6736%2825%2902165-8)
- [ClinicalTrials.gov (NCT05872620)](https://clinicaltrials.gov/study/NCT05872620)

## The compound

- [Orforglipron: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

## With this study

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Orforglipron

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026) Randomized trial · people · 2026
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026) Randomized trial · people · 2026
- [Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1](https://pepvault.app/research/orforglipron-attain-1-2025) Randomized trial · people · 2025
- [Orforglipron: food lowered drug exposure by 17.6% to 23.7%](https://pepvault.app/research/orforglipron-ma-2024) Clinical trial · people · 2024
- [Every study on Orforglipron](https://pepvault.app/research#orforglipron)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Orforglipron](https://pepvault.app/research#orforglipron)

## The library

- [Orforglipron](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
